Last patient completes final visit in SARA-INT, a Phase 2

BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA

9 November 2026

Biophytis announces the operational launch of its joint venture in China. Biophytis announces the creation of the Chinese subsidiary of its Hong Kong joint venture, named Biophytis Biopharmaceutical Shenzhen, located…

Biophytis reports first-half 2026 results and provides an update on its strategy

30 October 2026

Biophytis reports its half-year financial results and provides an update on its strategic outlook.

Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity

11 September 2026

Biophytis today announces the completion of a capital increase through the issue of new shares, accompanied by share subscription warrants, with the removal of the preferential subscription rights of the…

Biophytis to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity

9 September 2026

Biophytis today announces that it has submitted to the Brazilian Health Regulatory Agency (ANVISA) an amendment to the protocol of the phase 2 OBA clinical study in obesity.

Biophytis strengthens its financial position and extends its cash runway into Q1 2027

31 August 2026

Cash position strengthened to €3.0 million Most 2026 share warrants exercised Phase 2 study in obesity to start in Q1 2027 Hong-Kong JV to start operations for preparing Phase 3…

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY

10 August 2026

Biophytis today announces that it has received approval from Brazil’s National Health Surveillance Agency (ANVISA) to begin the Phase 2 OBA clinical trial for obesity in Brazil and shares the…

Last patient completes final visit in SARA-INT, a Phase 2 clinical trial evaluating the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia

Other Press Releases

BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA

Biophytis reports first-half 2026 results and provides an update on its strategy

Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity

Biophytis to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity

Biophytis strengthens its financial position and extends its cash runway into Q1 2027

BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY

Addresses

Addresses

Addresses